24/7 Emergency & General Advisory
🚨 24/7 Medical Emergency
Non-Emergency Advisory
10:00 AM – 6:00 PM, Mon–Sat
For appointments & general queries.
Join our healthcare community
GLP-1 medications — a class that includes Ozempic, Wegovy, Mounjaro, and Zepbound — mimic a natural gut hormone to lower blood sugar and reduce appetite. Originally approved for type 2 diabetes, this drug class has expanded into treatment for obesity, heart disease, sleep apnea, and more, with new o
GLP-1 medications are a class of drugs that mimic glucagon-like peptide-1, a hormone your gut naturally releases after eating. They work by boosting insulin release, slowing digestion, and signaling fullness to the brain — which is why the same drug class treats both type 2 diabetes and obesity.
The first GLP-1 receptor agonist was approved by the FDA for type 2 diabetes back in 2005. Since then, the class has grown well beyond diabetes care, now covering chronic weight management, cardiovascular risk reduction, and several other conditions, with new drugs and formulations still being approved.
GLP-1 receptor agonists activate the same receptors your body's natural GLP-1 hormone would. This triggers your pancreas to release more insulin when blood sugar rises, which helps control glucose levels in people with type 2 diabetes.
At the same time, these drugs slow down how quickly food leaves your stomach and act on appetite centers in the brain, which is what produces the strong feeling of fullness — and the weight loss — that made this drug class famous. Some newer medications, like tirzepatide, go a step further by also activating a second gut hormone receptor (GIP), which appears to amplify both the blood-sugar and weight-loss effects.
As of mid-2026, there are more than a dozen FDA-approved GLP-1 or GLP-1/GIP combination medications on the U.S. market, spanning both diabetes and weight-management indications.
For type 2 diabetes: Ozempic and Rybelsus (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide), and Victoza (liraglutide).
For chronic weight management: Wegovy and the newer oral Wegovy pill (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), and Foundayo (orforglipron) — a newer once-daily oral medication approved in April 2026 that, unlike the other pills in this class, isn't a peptide and doesn't require food or water timing restrictions.
The FDA also approved a higher 7.2 mg dose of injectable Wegovy in March 2026, which showed a mean weight loss of about 20.7% at 72 weeks in clinical trials, compared with roughly 17.5% for the earlier 2.4 mg dose. Several next-generation candidates, including retatrutide and CagriSema, remain in late-stage trials and haven't been approved yet, despite showing strong weight-loss results so far.
GLP-1 medications have moved well past their original purpose. Semaglutide (Wegovy) is now FDA-approved to reduce the risk of major cardiovascular events — heart attack, stroke, or cardiovascular death — in people with established heart disease, not just to help them lose weight. Tirzepatide (Zepbound) has also been approved for obstructive sleep apnea in adults with obesity, the first medication ever cleared specifically for that condition.
Other indications under active FDA review include heart failure with preserved ejection fraction and peripheral artery disease. Researchers are also studying GLP-1s for conditions like binge eating disorder and substance use disorders, though those uses aren't FDA-approved and remain in earlier stages of clinical research.
Gastrointestinal side effects are, by far, the most common issue with this drug class. Research published in Mayo Clinic Proceedings found that 40% to 70% of patients experience gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, and delayed stomach emptying, particularly when starting the medication or increasing the dose. These symptoms often improve with smaller, more frequent meals, adequate hydration, and avoiding high-fat or high-sugar foods, and they tend to ease over time for many patients.
Serious complications are less common but worth knowing about. Gallbladder problems and, rarely, acute pancreatitis have been reported. Because these drugs slow gastric emptying, there's also an increased risk of retained stomach contents during procedures requiring sedation or anesthesia, which is why patients are often asked to follow specific fasting instructions or pause the medication before surgery or endoscopy. Long-term studies have not confirmed a clear link to pancreatic cancer, but Mayo Clinic notes that GLP-1 agonists have been associated with certain thyroid tumors in animal studies, which is the basis for one of the drug class's key contraindications.
According to Mayo Clinic, GLP-1 agonists generally aren't recommended for people who have had medullary thyroid cancer or who have a personal or family history of multiple endocrine neoplasia type 2 (MEN2), a rare genetic syndrome. They're also generally avoided during pregnancy, while trying to conceive, or while breastfeeding, and may not be appropriate for people with certain intestinal conditions like gastroparesis or specific types of kidney disease.
People taking other blood-sugar-lowering medications, such as insulin or sulfonylureas, face a higher risk of hypoglycemia (low blood sugar) when combined with a GLP-1, and may need dose adjustments under medical supervision.
Compounded semaglutide and other non-FDA-approved versions of GLP-1 drugs circulated widely during periods of brand-name shortage, but their quality and dosing accuracy aren't independently verified the way FDA-approved products are. The FDA has taken enforcement action against some compounding operations in 2026, and Mayo Clinic experts caution that using an unregulated version means you can't be fully sure what's actually in the product. If cost or availability is pushing you toward a compounded option, that's worth raising directly with your doctor rather than sourcing it independently.
What does GLP-1 stand for? GLP-1 stands for glucagon-like peptide-1, a natural hormone released by your gut after eating. GLP-1 medications are designed to mimic this hormone's effects on insulin release, appetite, and digestion.
Are GLP-1 medications only for diabetes? No. While the class was originally developed for type 2 diabetes, several GLP-1 drugs are now FDA-approved for chronic weight management, cardiovascular risk reduction in people with heart disease, and obstructive sleep apnea, with other uses under review.
What are the most common GLP-1 side effects? Gastrointestinal symptoms are most common, affecting an estimated 40% to 70% of patients, according to Mayo Clinic Proceedings. These include nausea, vomiting, diarrhea, and constipation, and they often improve over the first few weeks of treatment.
Do you have to take GLP-1 medications forever? Most clinicians expect GLP-1s to be a long-term or lifelong treatment for chronic conditions like diabetes and obesity, similar to other medications for chronic disease, since benefits like weight loss and blood sugar control tend to reverse after stopping.
Is there an oral GLP-1 pill available now? Yes. Oral semaglutide (the Wegovy pill) and Foundayo (orforglipron) are both FDA-approved oral GLP-1 medications for weight management as of 2026, alongside the long-available oral diabetes medication Rybelsus.
GLP-1 medications have moved from a niche diabetes treatment to one of the most widely prescribed drug classes in medicine, and the list of approved uses is still growing. Whether one is right for you depends on your specific health history, not just what's trending — which makes an honest conversation with your doctor about your goals, your medical history, and your tolerance for gastrointestinal side effects the most useful first step.
Mayo Clinic — "Diabetes drugs and weight loss" (expert answers)
Mayo Clinic Proceedings — "GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians"
Mayo Clinic Press — "Beyond Ozempic: The GLP-1 boom"
Stanford Medicine — "GLP-1s 101: What the science says about weight loss, side effects, safety"
U.S. Food and Drug Administration (FDA) — GLP-1 receptor agonist approvals
PMC/NCBI — "Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks"
Visit Hospital
Near You
Does intermittent fasting weight loss actually last? A 2026 one-year follow-up study says yes — people who did just 12 weeks of time-restricted eating kept more weight off a full year later than those who got standard diet advice alone. But a separate Cochrane review of nearly 2,000 adults found int
July 23, 2026
Scientists at the University of Cambridge tested 39 common sweeteners against 25 species of gut bacteria in the lab. About three-quarters of the sweeteners changed how at least one bacterial species grew, and effects got stronger — or weaker — when sweeteners were combined with medications, caffeine
July 23, 2026
A study of nearly 13,000 Brazilian adults found that people who consumed the most artificial sweeteners had noticeably faster memory and thinking decline over eight years than those who consumed the least. The effect was strongest in adults under 60 and in people with diabetes. Researchers stress th
July 23, 2026